The latest advances in liquid biopsy for lung cancer-a narrative review.

IF 4 2区医学 Q2 ONCOLOGY Translational lung cancer research Pub Date : 2024-11-30 Epub Date: 2024-11-27 DOI:10.21037/tlcr-24-828

Wei She, Yago Garitaonaindia, Yun Lin

{"title":"The latest advances in liquid biopsy for lung cancer-a narrative review.","authors":"Wei She, Yago Garitaonaindia, Yun Lin","doi":"10.21037/tlcr-24-828","DOIUrl":null,"url":null,"abstract":"Background and objective: Liquid biopsy has emerged as a transformative approach in the diagnosis, monitoring, and treatment of lung cancer. This review aims to provide an updated overview of the latest advancements in liquid biopsy for lung cancer, highlighting the key developments and their clinical implications.Methods: A comprehensive literature search was conducted using databases, such as PubMed, Embase, and Web of Science, covering the period from January 2018 to July 2024. The search terms included \"liquid biopsy\", \"lung cancer\", \"circulating tumor DNA\", \"circulating tumor cells\", and \"exosomes\". Studies were selected based on their relevance, novelty, and impact on the field.Key content and findings: The review discusses recent innovations in liquid biopsy technologies, including improvements in the sensitivity and specificity of these technologies, and the role of various biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, circulating tumor RNA (ctRNA), extracellular vesicles (EVs), tumor metabolites, tumor-educated platelets (TEPs), and plasma protein biomarkers, in early detection, prognosis, and personalized therapy. It also examines challenges and future directions for integrating liquid biopsy into routine clinical practice.Conclusions: Liquid biopsy represents a promising non-invasive diagnostic tool for lung cancer and has significant potential to enhance patient outcomes. It is anticipated that continued research and technological advancements will further refine its clinical utility, potentially transforming the landscape of lung cancer management.","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"13 11","pages":"3241-3251"},"PeriodicalIF":4.0000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11632431/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational lung cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tlcr-24-828","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: Liquid biopsy has emerged as a transformative approach in the diagnosis, monitoring, and treatment of lung cancer. This review aims to provide an updated overview of the latest advancements in liquid biopsy for lung cancer, highlighting the key developments and their clinical implications.

Methods: A comprehensive literature search was conducted using databases, such as PubMed, Embase, and Web of Science, covering the period from January 2018 to July 2024. The search terms included "liquid biopsy", "lung cancer", "circulating tumor DNA", "circulating tumor cells", and "exosomes". Studies were selected based on their relevance, novelty, and impact on the field.

Key content and findings: The review discusses recent innovations in liquid biopsy technologies, including improvements in the sensitivity and specificity of these technologies, and the role of various biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, circulating tumor RNA (ctRNA), extracellular vesicles (EVs), tumor metabolites, tumor-educated platelets (TEPs), and plasma protein biomarkers, in early detection, prognosis, and personalized therapy. It also examines challenges and future directions for integrating liquid biopsy into routine clinical practice.

Conclusions: Liquid biopsy represents a promising non-invasive diagnostic tool for lung cancer and has significant potential to enhance patient outcomes. It is anticipated that continued research and technological advancements will further refine its clinical utility, potentially transforming the landscape of lung cancer management.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肺癌液体活检的最新进展——述评。

背景和目的：液体活检已经成为肺癌诊断、监测和治疗的一种变革性方法。本文综述了肺癌液体活检的最新进展，重点介绍了主要进展及其临床意义。方法：采用PubMed、Embase、Web of Science等数据库进行综合文献检索，检索时间为2018年1月~ 2024年7月。搜索词包括“液体活检”、“肺癌”、“循环肿瘤DNA”、“循环肿瘤细胞”和“外泌体”。研究是根据其相关性、新颖性和对该领域的影响来选择的。主要内容和发现：本文讨论了液体活检技术的最新创新，包括这些技术的敏感性和特异性的改进，以及各种生物标志物的作用，包括循环肿瘤DNA （ctDNA）、循环肿瘤细胞（CTCs）、外泌体、循环肿瘤RNA （ctRNA）、细胞外囊泡（ev）、肿瘤代谢物、肿瘤诱导血小板（TEPs）和血浆蛋白生物标志物，在早期检测、预后和个性化治疗中的作用。它也检查挑战和未来的方向整合液体活检纳入常规临床实践。结论：液体活检是一种很有前途的非侵入性肺癌诊断工具，具有显著的提高患者预后的潜力。预计持续的研究和技术进步将进一步完善其临床应用，潜在地改变肺癌管理的格局。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Translational lung cancer research Medicine-Oncology

CiteScore

7.20

自引率

2.50%

发文量

137

期刊介绍： Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.